clinical trial · NCT06387342
Namodenoson Treatment of Advanced Pancreatic Cancer
Can-Fite BioPharma·phase2·recruiting·n = 20
Pancreatic AdenocarcinomaPancreatic CancerNamodenoson 25mg
brief summary
This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
started
Nov 10, 2024
primary completion
Jul 15, 2026
completion
Dec 15, 2026
last updated
Jan 31, 2025
detailed description
All patients will receive the study drug twice daily. The study drug is given as a capsule, orally (by mouth). Patients will be monitored regularly for safety. Tumor imaging will be performed approximately every two months. Patients can decide to stop the treatment with study drug at any time.
official title
CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol